We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · September 29, 2022

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced NSCLC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study
J. Clin. Oncol 2022 Sep 07;[EPub Ahead of Print], O Adotévi, D Vernerey, P Jacoulet, A Meurisse, C Laheurte, H Almotlak, M Jacquin, V Kaulek, L Boullerot, M Malfroy, E Orillard, G Eberst, A Lagrange, L Favier, M Gainet-Brun, L Doucet, L Teixeira, Z Ghrieb, AL Clairet, Y Guillaume, M Kroemer, D Hocquet, M Moltenis, S Limat, E Quoix, C Mascaux, D Debieuvre, C Fagnoni-Legat, C Borg, V Westeel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading